Výsledky vyhledávání

Thin-walled cavities, cysts, and pneumothorax in Pneumocystis carinii pneumonia: further observations with histopathologic correlation

Autor: Harvey I. Pass, A Archer, William D. Travis, J Falloon, I M Feurestein, J M Pluda, P S Francis, Henry Masur

Publikováno v: Radiology. 174:697-702

Thin-walled pulmonary cystic lesions were found in five immunocompromised patients, four with acquired immunodeficiency syndrome (AIDS). Four patients had Pneumocystis carinii pneumonia (PCP), and one had pulmonary lesions and disseminated P carinii

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd526e872a665c9e41b2a40e5187d356
https://doi.org/10.1148/radiology.174.3.2305052

Zobrazit plný text záznamu

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

Autor: J E, Tseng, B S, Glisson, F R, Khuri, D M, Shin, J N, Myers, A K, El-Naggar, J S, Roach, L E, Ginsberg, P F, Thall, X, Wang, S, Teddy, K N, Lawhorn, R E, Zentgraf, G D, Steinhaus, J M, Pluda, J L, Abbruzzese, W K, Hong, R S, Herbst

Publikováno v: Cancer. 92(9)

Thalidomide has been shown to have antiangiogenic effects in preclinical models as well as a significant antitumor effect in hematologic tumors such as multiple myeloma. The authors performed this Phase II study to determine the activity, toxicity pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::738a37722e49f27c613584ff8d27cbc4
https://pubmed.ncbi.nlm.nih.gov/11745292

Zobrazit plný text záznamu

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer

Autor: W D, Figg, W, Dahut, P, Duray, M, Hamilton, A, Tompkins, S M, Steinberg, E, Jones, A, Premkumar, W M, Linehan, M K, Floeter, C C, Chen, S, Dixon, D R, Kohler, E A, Krüger, E, Gubish, J M, Pluda, E, Reed

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 7(7)

Thalidomide is a potent teratogen that causes dysmelia in humans. Recently, in vitro data suggested that it inhibits angiogenesis. Prostate cancer is dependent on the recruitment of new blood vessels to grow and metastasize. Based on those data, we i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::373d65a32e0ce6b7493fd0f647c4fdd0
https://pubmed.ncbi.nlm.nih.gov/11448901

Zobrazit plný text záznamu

Drug-induced lupus associated with COL-3: report of 3 cases

Autor: J V, Ghate, M L, Turner, M A, Rudek, W D, Figg, W, Dahut, V, Dyer, J M, Pluda, E, Reed

Publikováno v: Archives of dermatology. 137(4)

Anti-angiogenesis is an exciting new approach to anticancer therapy. COL-3, a tetracycline derivative, is a novel anti-angiogenesis agent with potent preclinical anticancer activity. During the conduct of a phase 1 clinical trial for refractory metas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f7299d5336787b7dec7e88044dc26ae2
https://pubmed.ncbi.nlm.nih.gov/11295928

Zobrazit plný text záznamu

A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer

Autor: K S, Bauer, W D, Figg, J M, Hamilton, E C, Jones, A, Premkumar, S M, Steinberg, V, Dyer, W M, Linehan, J M, Pluda, E, Reed

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5(9)

We conducted a Phase II clinical trial of the antiproliferative, antimetastatic, and antiangiogenic agent carboxyamido-triazole (CAI), using pharmacokinetic assessment to guide drug dosing. Fifteen patients who had stage D2 androgen-independent prost

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::628dff6535586f6b315504646b329fbf
https://pubmed.ncbi.nlm.nih.gov/10499600

Zobrazit plný text záznamu

O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair

Autor: T P, Spiro, S L, Gerson, L, Liu, S, Majka, J, Haaga, C L, Hoppel, S T, Ingalls, J M, Pluda, J K, Willson

Publikováno v: Cancer research. 59(10)

Early phase evaluation of anticancer drugs has traditionally used toxicity (usually hematological) rather than efficacy end points to establish appropriate dosing schedules. To establish a biochemical efficacy end point for overcoming alkylguanine DN

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8010eb1ad8a111844d619c60f49d4e11
https://pubmed.ncbi.nlm.nih.gov/10344750

Zobrazit plný text záznamu

Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies

Autor: J M, Pluda

Publikováno v: Seminars in oncology. 24(2)

Compelling data implicate angiogenesis and tumor-associated neovascularization as a central pathogenic step in the process of tumor growth, invasion, and metastasis. These complex processes involve multiple steps and pathways dependent on the local b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0286bfc41f08525e4f9a70597f2081a3
https://pubmed.ncbi.nlm.nih.gov/9129690

Zobrazit plný text záznamu

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute

Autor: M C, Christian, J M, Pluda, P T, Ho, S G, Arbuck, A J, Murgo, E A, Sausville

Publikováno v: Seminars in oncology. 24(2)

The Division of Cancer Treatment, Diagnosis and Centers of the National Cancer Institute (NCI) has a large program in clinical cancer therapeutics development. It currently holds investigational new drug applications for nearly 200 agents with which

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fac8d491481ac921845ba42cfeac0f83
https://pubmed.ncbi.nlm.nih.gov/9129691

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání